Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Polpharma SA
Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.
Following a years-long back-and-forth to establish exclusivity protection for its Tecfidera multiple-sclerosis treatment in Europe, Biogen has ultimately seen the CHMP recommend three generic versions to receive pan-European marketing authorization.
An insomnia drug to improve daytime functioning, a treatment for a rare type of eye cancer, and an oral migraine drug for both acute and preventive treatment are among 13 new products recommended for pan-EU approval.
After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Polpharma Biologics